2024
BIO101 + GLP-1RA to prevent potential muscle loss in patients with overweight and obesity: the OBA study, Rob van Maanen MD MBA, Chief Medical Officer, SCWD 2024, Washington DC, USA
BIO101: a drug candidate to reduce GLP-1RA-induced muscle mass or function loss in patients with obesity, Rob Van Maanen, Claudia Ferreira, Mathilde Latil, Serge Camelo, Sandrine Rabut, Stanislas Veillet, Pierre J. Dilda, Waly Dioh, Marc-Andre Cornier, Poster 9-11 Session 2.5. SCWD 2024, Washington DC, USA
BIO101, a drug candidate to counter-act age-related sarcopenia: towards Phase 3 program, Waly Dioh PhD, Cendrine Tourette, PhD, Sandrine Rabut, PharmD, Roger Fielding, PhD, Jean Mariani, MD, PhD, Rob Van Maanen, MD and Stanislas Veillet, PhD
Optimising Obesity Clinical Trials: From Site Selection to Patient Reach, BIO101 + GLP-1RA to prevent muscle loss in patients with overweight and obesity: the OBA study, Presentation at 2nd Annual Clinical Outsourcing Group Europe, 12th-13th November 2024
Results of two clinical trials in vulnerable populations support the evaluation of BIO101 (20-hydroxyecdysone), a MAS Receptor activator as a candidate oral treatment for rare pediatric neuromuscular diseases, Cendrine Tourette, Waly Dioh, Sandrine Rabut, Serge Camelo, Jean Mariani, Rob Van Maanen, Stanislas Veillet
BIO101 drug candidate development in rare neuromuscular diseases: Cardiorespiratory and motor unit preclinical evaluation in DMD and in SMA, Pierre Dilda, Cynthia Bézier, Robin Deloux, René Lafont, Stanislas Veillet, Frédéric Charbonnier, Olivier Biondi, Mathilde Latil
BIO101 as a candidate oral treatment for DMD patients is supported by the results of two randomized clinical trials in
vulnerable populations, Cendrine Tourette, Waly Dioh, Sandrine Rabut, Serge Camelo, Jean Mariani, Rob Van Maanen, Stanislas Veillet